Meadow Memorials | $9,000,000 | (Mar 24, 2026)
Oryon Cell Therapies | $21,000,000 | (Mar 24, 2026)
Avtal | $24,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
MBrace Therapeutics
start up
United States
- San Diego, California
- 15/11/2023
- Series B
- $85,000,000
MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.
- Industry Biotechnology Research
- Website https://mbracetrx.com/
- LinkedIn https://www.linkedin.com/company/mbrace-therapeutics/about/
Claros | $30,000,000 | (Mar 20, 2026)
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)